Transaction Description
Gemstone capital acted as financial advisor in Stenocare’s Rights Issue. The issue offered 2,335,224 new shares at a subscription price per share of 4.58 DKK, as the offer is for a unit, which includes two shares, the subscription price for a unit is 9.16 DKK, corresponding to maximum gross proceeds in cash of 10.7 mDKK. Stenocare obtained pre-subscription commitments in cash of 3.2 mDKK (30%) and guarantee commitments of 6.1 mDKK (56.5%) which corresponds to minimum proceeds of 9.3 mDKK (86.5%). T he Rights Issue was subscribed to approximately 13.6 DKK million including pre-subscriptions of approximately 3.2 DKK million, which corresponds to a total subscription rate of approximately 127 percent. Consequently, none of the guarantors (approximately 6.0 DKK million) was called and a reduced allocation was applied to subscribers without rights. The Company was thus provided with approximately 10.7 DKK million in gross proceeds before deduction of transaction-related costs.
Contact Person
Company Description
Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme. Simoultaneously, Stenocare is the first Danish company to have obtained approval for medical oil-based cannabis products for the Danish pilot Programme. Today, Stenocare operates in Denmark, Sweden, Norway, Germany, the UK, and Australia.
Financial and strategic advisors
to high caliber growth companies
in pursuit of market leadership.
© 2024 Gemstone Capital – Designet af Aveo web&marketing